suPAR is a biomarker and therapeutic target for AKI

More Details

More Details

Catalytic iron is a biomarker

and therapeutic target in AKI

More Details

A common genetic variant in HO-1 predicts risk of AKI following cardiac surgery

More Details

Immune checkpoint inhibitors cause AKI through tubulo-interstitial nephritis

More Details

FGF23 is an early marker of AKI and death after cardiac surgery and in critically ill patients.

Research

An overview of our projects

Publications

A portfolio with a list of our publications

Bio

Get to know more about the PI

Team

Get to know more about our team

The Leaf Lab conducts patient-oriented research in acute kidney injury (AKI). Our goal is to develop novel approaches to prevent AKI, and to improve outcomes in patients who suffer from AKI. Read more about AKI.

Our research is highly collaborative and interdisciplinary and includes:

•  Randomized trials
•  Biomarker studies
•  Genetics
•  Epidemiology

News

NIH R01 Grant

September 1, 2020
David Leaf was awarded an R01 grant from the NIH/NIDDK for his proposal entitled, “Deferoxamine for the Prevention of Acute Kidney Injury.”

NIH R01 Grant

May 1, 2019
David Leaf was awarded an R01 grant from the NIH/NHLBI for his proposal entitled, “Precision Medicine Approach to Vitamin D3 Administration in Critically Ill Patients.”

Gottschalk Grant

July 1, 2018
David Leaf was awarded a Carl W. Gottschalk Research Scholar Grant to study, “Hepcidin, Dysregulated Iron Homeostasis, and Anemia in Human AKI” from the American Society of Nephrology Foundation for Kidney Research.